Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 5/2013

Open Access 01-10-2013 | Original Paper

Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer

Authors: Eva J. Vlug, Robert A. H. van de Ven, Jeroen F. Vermeulen, Peter Bult, Paul J. van Diest, Patrick W. B. Derksen

Published in: Cellular Oncology | Issue 5/2013

Login to get access

Abstract

Background

Yes Associated Protein (YAP) has been implicated in the control of organ size by regulating cell proliferation and survival. YAP is a transcriptional coactivator that controls cellular responses through interaction with TEAD transcription factors in the nucleus, while its transcriptional functions are inhibited by phosphorylation-dependent translocation to the cytosol. YAP overexpression has been associated with different types of cancer, such as lung, skin, prostate, ovary and liver cancer. Recently, YAP was linked to E-cadherin-dependent regulation of contact inhibition in breast cancer cells.

Results

In this study we examined YAP protein expression and cellular localization in 237 cases of human invasive breast cancer by immunohistochemistry and related its expression to clinicopathological features and E-cadherin expression. We observed that invasive lobular carcinoma is characterized by higher expression levels of both nuclear and cytosolic YAP (p < 0.001). Nuclear YAP expression did not associate with other variables such as lymph node involvement, tumor grade, tumor size, mitotic activity or the molecular sub-types of invasive breast cancer. We observed that high nuclear and cytosolic YAP expression are associated with the E-cadherin deficient breast cancer subtype ILC (p < 0.001) and cell lines derived from human breast cancers and conditional mouse models of human lobular breast cancer.

Conclusions

Since our data indicate that nuclear YAP localization is more common in breast cancers lacking functional adherens junctions, it suggests that YAP-mediated transcription may be involved in the development and progression of invasive lobular breast cancer.
Appendix
Available only for authorised users
Literature
1.
G. Berx, A.M. Cleton-Jansen, F. Nollet, W.J. de Leeuw, M. van de Vijver et al., E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J 14, 6107–6115 (1995)PubMed
2.
R. Moll, M. Mitze, U.H. Frixen, W. Birchmeier, Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 143, 1731–1742 (1993)PubMed
3.
C.B. Vos, A.M. Cleton-Jansen, G. Berx, W.J. de Leeuw, N.T. ter Haar et al., E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. Br J Cancer 76, 1131–1133 (1997)PubMedCrossRef
4.
P.W. Derksen, X. Liu, F. Saridin, H. van der Gulden, J. Zevenhoven et al., Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. Cancer Cell 10, 437–449 (2006)PubMedCrossRef
5.
P.W. Derksen, T.M. Braumuller, E. van der Burg, M. Hornsveld, E. Mesman et al., Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. Dis Model Mech 4, 347–358 (2011)PubMedCrossRef
6.
M. Lombaerts, T. van Wezel, K. Philippo, J.W. Dierssen, R.M. Zimmerman et al., E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines. Br J Cancer 94, 661–671 (2006)PubMed
7.
R. Kalluri, R.A. Weinberg, The basics of epithelial-mesenchymal transition. J Clin Invest 119, 1420–1428 (2009)PubMedCrossRef
8.
B.A. Edgar, From cell structure to transcription: Hippo forges a new path. Cell 124, 267–273 (2006)PubMedCrossRef
9.
J. Huang, S. Wu, J. Barrera, K. Matthews, D. Pan, The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP. Cell 122, 421–434 (2005)PubMedCrossRef
10.
S. Wu, J. Huang, J. Dong, D. Pan, hippo encodes a Ste-20 family protein kinase that restricts cell proliferation and promotes apoptosis in conjunction with salvador and warts. Cell 114, 445–456 (2003)PubMedCrossRef
11.
X. Wei, T. Shimizu, Z.C. Lai, Mob as tumor suppressor is activated by Hippo kinase for growth inhibition in Drosophila. EMBO J 26, 1772–1781 (2007)PubMedCrossRef
12.
J. Dong, G. Feldmann, J. Huang, S. Wu, N. Zhang et al., Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130, 1120–1133 (2007)PubMedCrossRef
13.
K. Schlegelmilch, M. Mohseni, O. Kirak, J. Pruszak, J.R. Rodriguez et al., Yap1 acts downstream of alpha-catenin to control epidermal proliferation. Cell 144, 782–795 (2011)PubMedCrossRef
14.
15.
F. Kanai, P.A. Marignani, D. Sarbassova, R. Yagi, R.A. Hall et al., TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins. EMBO J 19, 6778–6791 (2000)PubMedCrossRef
16.
A. Komuro, M. Nagai, N.E. Navin, M. Sudol, WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 278, 33334–33341 (2003)PubMedCrossRef
17.
S. Dupont, L. Morsut, M. Aragona, E. Enzo, S. Giulitti et al., Role of YAP/TAZ in mechanotransduction. Nature 474, 179–183 (2011)PubMedCrossRef
18.
N.G. Kim, E. Koh, X. Chen, B.M. Gumbiner, E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A 108, 11930–11935 (2011)PubMedCrossRef
19.
D. Matallanas, D. Romano, K. Yee, K. Meissl, L. Kucerova et al., RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein. Mol Cell 27, 962–975 (2007)PubMedCrossRef
20.
K. Wada, K. Itoga, T. Okano, S. Yonemura, H. Sasaki, Hippo pathway regulation by cell morphology and stress fibers. Development 138, 3907–3914 (2011)PubMedCrossRef
21.
B. Zhao, L. Li, K. Tumaneng, C.Y. Wang, K.L. Guan, A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 24, 72–85 (2010)PubMedCrossRef
22.
B. Zhao, L. Li, L. Wang, C.Y. Wang, J. Yu et al., Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 26, 54–68 (2012)PubMedCrossRef
23.
M. Perrais, X. Chen, M. Perez-Moreno, B.M. Gumbiner, E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. Mol Biol Cell 18, 2013–2025 (2007)PubMedCrossRef
24.
M. Overholtzer, J. Zhang, G.A. Smolen, B. Muir, W. Li et al., Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 103, 12405–12410 (2006)PubMedCrossRef
25.
X. Wang, L. Su, Q. Ou, Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur. J. Cancer. (2011)
26.
J. Zhang, J.Y. Ji, M. Yu, M. Overholtzer, G.A. Smolen et al., YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway. Nat Cell Biol 11, 1444–1450 (2009)PubMedCrossRef
27.
M. Cordenonsi, F. Zanconato, L. Azzolin, M. Forcato, A. Rosato et al., The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147, 759–772 (2011)PubMedCrossRef
28.
R. Tufail, M. Jorda, W. Zhao, I. Reis, Z. Nawaz, Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas. Breast Cancer Res Treat 131, 743–750 (2011)PubMedCrossRef
29.
G.M. Hampton, A. Mannermaa, R. Winqvist, M. Alavaikko, G. Blanco et al., Loss of heterozygosity in sporadic human breast carcinoma: a common region between 11q22 and 11q23.3. Cancer Res 54, 4586–4589 (1994)PubMed
30.
J. Gudmundsson, R.B. Barkardottir, G. Eiriksdottir, T. Baldursson, A. Arason et al., Loss of heterozygosity at chromosome 11 in breast cancer: association of prognostic factors with genetic alterations. Br J Cancer 72, 696–701 (1995)PubMedCrossRef
31.
S.L. Carter, M. Negrini, R. Baffa, D.R. Gillum, A.L. Rosenberg et al., Loss of heterozygosity at 11q22-q23 in breast cancer. Cancer Res 54, 6270–6274 (1994)PubMed
32.
I.P. Tomlinson, J.E. Strickland, A.S. Lee, L. Bromley, M.F. Evans et al., Loss of heterozygosity on chromosome 11 q in breast cancer. J Clin Pathol 48, 424–428 (1995)PubMedCrossRef
33.
R. Winqvist, G.M. Hampton, A. Mannermaa, G. Blanco, M. Alavaikko et al., Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis. Cancer Res 55, 2660–2664 (1995)PubMed
34.
M. Yuan, V. Tomlinson, R. Lara, D. Holliday, C. Chelala et al., Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15, 1752–1759 (2008)PubMedCrossRef
35.
Y.Y. Chen, E.S. Hwang, R. Roy, S. DeVries, J. Anderson et al., Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol 33, 1683–1694 (2009)PubMedCrossRef
36.
P. van der Groep, A. Bouter, R. van der Zanden, I. Siccama, F.H. Menko et al., Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 59, 611–617 (2006)PubMedCrossRef
37.
J. Packeisen, E. Korsching, H. Herbst, W. Boecker, H. Buerger, Demystified…tissue microarray technology. Mol Pathol 56, 198–204 (2003)PubMedCrossRef
38.
P.J. van Diest, No consent should be needed for using leftover body material for scientific purposes. BMJ 325, 648–651 (2002)PubMedCrossRef
39.
M. Tirkkonen, M. Tanner, R. Karhu, A. Kallioniemi, J. Isola et al., Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes Cancer 21, 177–184 (1998)PubMedCrossRef
40.
T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869–10874 (2001)PubMedCrossRef
41.
R.C. Schackmann, M. van Amersfoort, J.H. Haarhuis, E.J. Vlug, V.A. Halim et al., Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. J Clin Invest 121, 3176–3188 (2011)PubMedCrossRef
42.
M. Christgen, H. Bruchhardt, C. Hadamitzky, C. Rudolph, D. Steinemann et al., Comprehensive genetic and functional characterization of IPH-926: a novel CDH1-null tumour cell line from human lobular breast cancer. J Pathol 217, 620–632 (2009)PubMedCrossRef
43.
P.W. Derksen, E. Tjin, H.P. Meijer, M.D. Klok, H.D. MacGillavry et al., Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci U S A 101, 6122–6127 (2004)PubMedCrossRef
44.
R. Christova, T. Oelgeschlager, Association of human TFIID-promoter complexes with silenced mitotic chromatin in vivo. Nat Cell Biol 4, 79–82 (2002)PubMedCrossRef
45.
M. van de Wetering, N. Barker, I.C. Harkes, M. van der Heyden, N.J. Dijk et al., Mutant E-cadherin breast cancer cells do not display constitutive Wnt signaling. Cancer Res 61, 278–284 (2001)PubMed
46.
B.C. Pestalozzi, D. Zahrieh, E. Mallon, B.A. Gusterson, K.N. Price et al., Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 26, 3006–3014 (2008)PubMedCrossRef
47.
H. Zhao, A. Langerod, Y. Ji, K.W. Nowels, J.M. Nesland et al., Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell 15, 2523–2536 (2004)PubMedCrossRef
48.
H.A. Lehr, A. Folpe, H. Yaziji, F. Kommoss, A.M. Gown, Cytokeratin 8 immunostaining pattern and E-cadherin expression distinguish lobular from ductal breast carcinoma. Am J Clin Pathol 114, 190–196 (2000)PubMedCrossRef
49.
B. Zhao, X. Ye, J. Yu, L. Li, W. Li et al., TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22, 1962–1971 (2008)PubMedCrossRef
50.
R.M. Densham, E. O’Neill, J. Munro, I. Konig, K. Anderson et al., MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol Cell Biol 29, 6380–6390 (2009)PubMedCrossRef
51.
B.M. McCartney, R.M. Kulikauskas, D.R. LaJeunesse, R.G. Fehon, The neurofibromatosis-2 homologue, Merlin, and the tumor suppressor expanded function together in Drosophila to regulate cell proliferation and differentiation. Development 127, 1315–1324 (2000)PubMed
52.
M. Ernkvist, K. Aase, C. Ukomadu, J. Wohlschlegel, R. Blackman et al., p130-angiomotin associates to actin and controls endothelial cell shape. FEBS J 273, 2000–2011 (2006)PubMedCrossRef
53.
V. Gagne, J. Moreau, M. Plourde, M. Lapointe, M. Lord et al., Human angiomotin-like 1 associates with an angiomotin protein complex through its coiled-coil domain and induces the remodeling of the actin cytoskeleton. Cell Motil Cytoskeleton 66, 754–768 (2009)PubMedCrossRef
Metadata
Title
Nuclear localization of the transcriptional coactivator YAP is associated with invasive lobular breast cancer
Authors
Eva J. Vlug
Robert A. H. van de Ven
Jeroen F. Vermeulen
Peter Bult
Paul J. van Diest
Patrick W. B. Derksen
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 5/2013
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-013-0143-7

Other articles of this Issue 5/2013

Cellular Oncology 5/2013 Go to the issue

Original Paper

Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines

Original Paper

DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype

Original Paper

Regulation of MLH1 mRNA and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study

Original Paper

FOXP3 expression and nodal metastasis of breast cancer

Erratum

Erratum to: DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype

Original Paper

The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits